WVP
ATXS

Worth Venture Partners’s Astria Therapeutics ATXS Stock Holding History

Worth Venture Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,904
Closed -$883K – 118
2020
Q2 		$883K Sell
22,904
-4,165
-15% -$148K 0.43% 36
2020
Q1 		$674K Buy
+27,069
New +$839K 0.41% 37

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Worth Venture Partners's ATXS Position: Q3 2020 in Review

Worth Venture Partners sold out of Astria Therapeutics (ATXS) in Q3 2020, closing a stake of 22,904 shares — an estimated $883K sold.

Worth Venture Partners first reported a position in ATXS in Q1 2020 and held it in 2 quarters. The position peaked at $883K in Q2 2020. 51 funds tracked by Wall St. Rank hold ATXS as of Q3 2020.

  • Worth Venture Partners reported no remaining Astria Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Worth Venture Partners sold 22,904 Astria Therapeutics shares in Q3 2020, an estimated $883K.
  • Worth Venture Partners first reported a position in Astria Therapeutics in Q1 2020 and held it in 2 quarters.
  • Worth Venture Partners's Astria Therapeutics position peaked at $883K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2020.

Based on Worth Venture Partners's 13F filing for Q3 2020, filed 16 Nov 2020.